University of Antioquia

Mayfield, OH's, Exceptional Smiles at Landerbrook Selected as a 2024 Top Patient Rated Dentist

Retrieved on: 
Vendredi, mars 22, 2024
Dental care, Dental implant, Attention, Private practice, Patient, Cleveland Clinic, Rutgers University, Multimedia, Dentist, University of Antioquia, Dentistry

MAYFIELD HEIGHTS, Ohio, March 22, 2024 /PRNewswire-PRWeb/ -- Conveniently located at 5825 Landerbrook Drive Suite #121 in Mayfield Heights, Ohio, Exceptional Smiles at Landerbrook is a well-respected dental practice known for its commitment to providing state-of-the-art dentistry with a personal touch. Exceptional Smiles at Landerbrook has been named a 2024 Top Patient Rated Dentist by Find Local Doctors, a reputable online directory that recognizes outstanding medical providers and dentists based on superior reviews and ratings from patients. The clinic offers a wide range of dental services, including general dentistry, restorative procedures, cosmetic treatments and emergency dental care. The practice is equipped to handle all types of dental needs, from routine cleanings and root canals to Invisalign, dental implants and more. In addition to their comprehensive services, Exceptional Smiles at Landerbrook goes above and beyond to make dental care convenient and enjoyable for patients. With same-day appointments, extended weekday hours and flexible payment options, the practice strives to give patients the attention and care they deserve.

Key Points: 
  • MAYFIELD HEIGHTS, Ohio, March 22, 2024 /PRNewswire-PRWeb/ -- Conveniently located at 5825 Landerbrook Drive Suite #121 in Mayfield Heights, Ohio, Exceptional Smiles at Landerbrook is a well-respected dental practice known for its commitment to providing state-of-the-art dentistry with a personal touch.
  • Exceptional Smiles at Landerbrook has been named a 2024 Top Patient Rated Dentist by Find Local Doctors , a reputable online directory that recognizes outstanding medical providers and dentists based on superior reviews and ratings from patients.
  • The clinic offers a wide range of dental services, including general dentistry, restorative procedures, cosmetic treatments and emergency dental care.
  • In addition to their comprehensive services, Exceptional Smiles at Landerbrook goes above and beyond to make dental care convenient and enjoyable for patients.

Photonics Research Reveals Potential for Next-Gen AR/VR and IoT

Retrieved on: 
Jeudi, décembre 14, 2023
Brain, Research, Internet of things, Electronics, Virtual reality, Algorithm, USD, Health, University, Photonics, 3D, University of Antioquia, Information technology, University of Southern California, Environment, DMD, Thought, Television, Computer data storage, Video game

WASHINGTON, Dec. 14, 2023 /PRNewswire/ -- The Optica Foundation today released more detailed information on information technology research funded by the 2023 Optica Foundation Challenge. Researchers Zaijun Chen, University of Southern California, USA, and Alejandro Velez-Zea, Universidad de Antioquia, Colombia, both proposed novel approaches to addressing the flow of data and information in consumer-centric technologies.

Key Points: 
  • WASHINGTON, Dec. 14, 2023 /PRNewswire/ -- The Optica Foundation today released more detailed information on information technology research funded by the 2023 Optica Foundation Challenge .
  • Chen and Velez-Zea are introducing unique, innovative ways to address these issues by lessening the network burden and creating more seamless interactions and realistic environments."
  • In today's existing process, optical signals need to be converted to the electrical domain as part of the flow of information.
  • Research from Alejandro Velez-Zea, Universidad de Antioquia, Colombia, seeks to deliver on that demand.

Mayfield Heights, Ohio's, Exceptional Smiles at Landerbrook is Recognized as a 2023 Top Patient Rated Dentist by Find Local Doctors

Retrieved on: 
Lundi, février 27, 2023
Dentist, Dental implant, Family, Cleveland Clinic, Patient, Dental care, Rutgers University, Doctor, University of Antioquia, Cleveland, Private practice, OH, Dentistry, Northwestern University

MAYFIELD HEIGHTS, Ohio, Feb. 27, 2023 /PRNewswire-PRWeb/ -- Exceptional Smiles at Landerbrook is a well-respected practice, located at 5825 Landerbrook Drive Suite #121 in Mayfield Heights, Ohio. The clinic has earned many superior reviews and five-star ratings from patients across multiple online sources, which has led Find Local Doctors to name Exceptional Smiles at Landerbrook as a 2023 Top Patient Rated Dentist. Find Local Doctors is a reliable and easy-to-navigate online directory that recognizes local medical providers and dentists who have outstanding reviews and ratings from patients. Exceptional Smiles at Landerbrook is a patient-centered practice that offers top-ranked dental services with some of the most advanced dental technology available. From the moment patients walk through the door, they realize the commitment to provide state-of-the-art dentistry with a personal touch. Exceptional Smiles at Landerbrook is equipped to handle all types of dental needs, including those that involve general dentistry as well as those that require restorative, cosmetic or emergency dental care. Their wide menu of services offers everything from routine cleanings and root canals to Invisalign, dental implants and much more. The team at this popular practice takes extra measures to make dental care convenient and enjoyable, offering same-day appointments, extended weekday hours and flexible payment options to give patients the attention they deserve.

Key Points: 
  • MAYFIELD HEIGHTS, Ohio, Feb. 27, 2023 /PRNewswire-PRWeb/ -- Exceptional Smiles at Landerbrook is a well-respected practice, located at 5825 Landerbrook Drive Suite #121 in Mayfield Heights, Ohio.
  • The clinic has earned many superior reviews and five-star ratings from patients across multiple online sources, which has led Find Local Doctors to name Exceptional Smiles at Landerbrook as a 2023 Top Patient Rated Dentist.
  • Find Local Doctors is a reliable and easy-to-navigate online directory that recognizes local medical providers and dentists who have outstanding reviews and ratings from patients.
  • Exceptional Smiles at Landerbrook is a patient-centered practice that offers top-ranked dental services with some of the most advanced dental technology available.

The National Society of Leadership and Success Expands Internationally to Create a New Generation of Global Leaders

Retrieved on: 
Mercredi, septembre 14, 2022
University, National Society, University of Antioquia, Program, Government, NSLS, Student, Leadership, Goal, Programming Development Manager, School, Heart, GLOBE, Management, Medicine, Universidad

MIAMI, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The National Society of Leadership and Success (NSLS) is expanding internationally to bring transformative leadership development to students, starting with two universities in Colombia.

Key Points: 
  • MIAMI, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The National Society of Leadership and Success (NSLS) is expanding internationally to bring transformative leadership development to students, starting with two universities in Colombia.
  • Enrollment at Universidad de Antioquia is already underway, and Universidad del Sinu will begin enrolling students in the coming weeks.
  • Through the NSLS leadership development course, students at both schools will learn vital leadership skills they can carry with them throughout their lives and careers.
  • Partnering with schools in Colombia is our first step toward supporting students all over the world and creating a global community of leaders.

Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Retrieved on: 
Mardi, août 2, 2022
BAI, AAIC, NIH, Registry, Neurodegeneration, RU, Person, Hoffmann-La Roche, Safety, Roche, Company, Biomarker, University of Antioquia, Precision medicine, APP, ARIA, Mutation, Alzheimer's disease, AU, Population, Immunoglobulin G, Brain, CH, NIA, National Institute on Aging, NO, Research, Banner, Government budget balance, Crenezumab, Autosome, Janssen Pharmaceuticals, Free, Magnetic resonance imaging, MRI, Amyloid beta, Genentech, GLOBE, GNA, CEO, Entorhinal cortex, PSEN1, Conference, GB, Eli Lilly and Company, Disease, Nasdaq, AC, ADAD, University, PSEN2, SG, Dementia, National Institute, Risk, API, Medical imaging, Pharmaceutical industry, EU

The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.

Key Points: 
  • The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • During the trial, the dose of crenezumab was increased more than seven-fold as knowledge about potential treatment approaches for Alzheimers disease evolved.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.
  • Led by the Banner Alzheimers Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimers disease.

AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference

Retrieved on: 
Vendredi, juillet 22, 2022
CH, Genentech, University, Asan Medical Center, University of Antioquia, Immunity, Doctor of Philosophy, Neurodegeneration, NO, JP, RU, Hoffmann-La Roche, Parallel, Safety, University of Ulsan College of Medicine, GB, Eli Lilly and Company, AD, Teaching hospital, Company, MD, Biomarker, Precision medicine, Janssen Pharmaceuticals, Ulsan College, AC, Mutation, API, AU, Pharmaceutical industry, EU

API ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel- group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab

Key Points: 
  • API ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel- group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
    Margarita Giraldo-Chica (Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia)
    Selecting appropriate meaningful change thresholds for trials of early (prodromal-to-mild) AD: A caregiver-rated, anchor-based analysis based on the Tauriel Study
    Minyoung Oh, MD, PhD, (Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea)
    Initial clinical scans using [18F]ACI-12589, a novel -synuclein PET-tracer
    Prof. Ruben Smith (Skne University Hospital, Lund, Sweden)
    Optimized ACI-24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and pyroglutamate Abeta, key pathological species of Alzheimers disease (AD)
    Biomarker-based development for optimized ACI-24, a novel candidate vaccine for the treatment and prevention of Alzheimers disease
    AC Immune SAis a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • The Companys two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials.AC Immunehas a strong track record of securing strategic partnerships with leading global pharmaceutical companies includingGenentech, a member of the Roche Group, Eli Lilly and Company, andJanssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3billionin potential milestone payments.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark ofAC Immune SAin CN, CH, GB, JP, and NO.

Landmark Alzheimer's Prevention Trial Unable to Show Significantly Slower Cognitive Decline in Inherited Form of Disease

Retrieved on: 
Jeudi, juin 16, 2022
Doctor of Philosophy, NIA, Neuroscience Group Field at Fox Cities Stadium, ADAD, Learning, PSEN1, University of Antioquia, National, Method, Person, Institute, AAIC, Address, Hoffmann-La Roche, PET, Knowledge, Federal Ministry of Budget and National Planning (Nigeria), Goal, Research, Free, National Institute on Aging, API, Crenezumab, Disease, Courage, Clinical trial, GNA, University, National Institute, Dementia, RO, Edema, MRI, Partnership, Mutation, AD, APOE4, ROG, Conference, Amyloid, Bleeding, Risk, NIH, Medical imaging, Pharmaceutical industry, Fine chemical, Alzheimer's disease, Ageing, MD, Genentech

PHOENIX, June 16, 2022 /PRNewswire/ -- A precedent-setting prevention trial in Colombia has found that the investigational medicine crenezumab did not slow or prevent decline in cognition or memory for cognitively healthy people with a rare genetic mutation that causes early-onset Autosomal Dominant Alzheimer's Disease (ADAD).

Key Points: 
  • Carriers of the rare mutation are virtually certain to develop Alzheimer's and tend to become cognitively impaired by around age 44.
  • It also established a precedent-setting commitment to the sharing of trial data and samples with the field to have the greatest possible impact.
  • The API ADAD Trial was the first NIH-supported and potentially label-enabling prevention trial of an investigational Alzheimer's disease-modifying treatment in persons at biological risk for the disease.
  • In addition to several ongoing prevention trials in cognitively unimpaired older adults with biomarker evidence of Alzheimer's disease, other prevention trials are in the planning stages.

AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Retrieved on: 
Jeudi, juin 16, 2022
Population, NO, AU, Ageing, Neurodegeneration, PSEN2, Disease, University, Janssen Pharmaceuticals, Conference, GLOBE, Eli Lilly and Company, Banner, Alzheimer's disease, University of Antioquia, Person, CEO, Brain, Free, National Institute on Aging, API, NASDAQ, Amyloid beta, Mutation, Autosome, NIH, ADAD, AAIC, Knowledge, BAI, Magnetic resonance imaging, Government budget balance, National Institute, CH, Dementia, ARIA, SG, Risk, NIA, Registry, PSEN1, AC, Immunoglobulin G, Hoffmann-La Roche, Precision medicine, Company, Research, Crenezumab, RU, GNA, Roche, APP, MRI, GB, Medical imaging, Pharmaceutical industry, EU, Genentech

LAUSANNE, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease.

Key Points: 
  • The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • We are grateful to all those involved in this landmark study, which will undoubtedly increase the scientific communitys understanding of pre-symptomatic Alzheimers disease and prevention studies conducted in this population.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.
  • Led by the Banner Alzheimers Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimers disease.

Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Retrieved on: 
Jeudi, juin 16, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, PSEN2, Disease, University, RO, Duchenne muscular dystrophy, Conference, Banner, Neurotoxicity, Spinal muscular atrophy, Alzheimer's disease, University of Antioquia, Person, Brain, Biotechnology, Free, National Institute on Aging, API, Autosome, Mutation, Neuromyelitis optica spectrum disorder, NIH, ADAD, III, AAIC, Knowledge, BAI, Magnetic resonance imaging, Lists of diseases, Government budget balance, National Institute, Neuroscience, Patient, ROG, Diagnosis, Dementia, ARIA, Risk, Biomedical Research, Multiple sclerosis, NIA, Duchenne, Registry, PSEN1, Collaboration, Gantenerumab, Immunoglobulin G, Hoffmann-La Roche, Research, Crenezumab, GNA, Family, Roche, APP, MRI, Head, Pharmaceutical industry, Medical imaging, Ageing, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimers Institute, today announced results from the Alzheimers Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimers Institute, today announced results from the Alzheimers Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial.
  • The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • Within its Alzheimers pipeline, Genentech is also evaluating the potential of gantenerumab in autosomal dominant Alzheimers disease, as well as for the prevention of sporadic Alzheimers and treatment of early Alzheimers in late stage clinical trials.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.